Featured Dataverses

In order to use this feature you must have at least one published or linked dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

61 to 70 of 265 Results
Ngari et.al 2024_Inpatient_post_discharge_mortality_under5s_with_anaemia_readme.txt
Jan 15, 2024 - Replication Data for: Inpatient and post-discharge mortality among children with anaemia and malaria parasitaemia in coastal Kenya: a cohort study
Plain Text - 7.2 KB - MD5: 5a4abc494682a79dbb1835d28e09895e
DocumentationReadme
Ngari et.al 2024_Inpatient_post_discharge_mortality_under5s_with_anaemia_script.do
Jan 15, 2024 - Replication Data for: Inpatient and post-discharge mortality among children with anaemia and malaria parasitaemia in coastal Kenya: a cohort study
Stata Syntax - 20.4 KB - MD5: fd7662d70df06ab1a282cb6d25076c33
CodeStata
PB-SAM_SAP_Final.docx.pdf
Jan 11, 2024 - Data for: Pancreatic Enzymes and Bile Acids: A Non-Antibiotic approach to Treat Intestinal Dysbiosis in Acutely Ill Severely Malnourished Children
Adobe PDF - 1.3 MB - MD5: 8b4ce8ea539247898403dee26921b232
Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Sep 15, 2023
Sang, Samuel; Datoo, Mehreen; Otieno, Edward; Muiruri, Charles; Gathuri, Emmaloise; Ngoto,Omar; Musembi, Janet; Bellamy, Duncan; Provstgaard-Morys, Samuel; Stockdale, Lisa; Aboagye, Jeremy; Woods, Daniel; Lawrie, Alison; Roberts, Rachel; Keter, Kelvias; Kimani, Domtila; Ndungu, Francis; Kapulu, Melissa; Njau, Irene; Orindi, Benedict; Ewer, Katie; Hill, Adrian V. S.; Bejon, Philip; Hamaluba, Mainga, 2023, "Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya", https://doi.org/10.7910/DVN/IRGZ35, Harvard Dataverse, V5, UNF:6:8VbuHGi8Xr05EETTLqzF9g== [fileUNF]
In the era of anti-malaria drug resistance and resistance to insecticide treated bed nets, there is an urgent need for a highly efficacious vaccine. We evaluated a candidate malaria vaccine incorporating the antigen R21 (part of the P. falciparum circumsporozoite malaria antigen co-expressed with hepatitis B antigen plus an adjuvant to boost the im...
CONSORT-2010-Checklist.pdf
CONSORT-2010-Checklist.pdf
Sep 15, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Adobe PDF - 66.3 KB - MD5: 4c2a8dc2345f6ceac36f9aa9a4489b89
Documentation
Figure 2.pptx
Sep 15, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
MS Powerpoint - 115.1 KB - MD5: 277a24fc702aa36b7fff9754fd9d08d6
Documentation
Figure S1.pptx
Sep 15, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
MS Powerpoint - 186.5 KB - MD5: 2e69c714f186d70db36f0afbead59af2
Documentation
VAC073_Supplementary tables.docx
Sep 15, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
MS Word - 50.6 KB - MD5: fc4f3365f9892434d47cb5d7ee31645c
Documentation
190325-R21 GROUP 1 CRF-Version 6.0 (004).pdf
Sep 7, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Adobe PDF - 1.8 MB - MD5: 93f3f60d8f02a450c139ae4ea097076e
Case Report Form
GROUP 2 CRF V 7.0 11 July 2019-ELT.pdf
Sep 7, 2023 - Data for: A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya
Adobe PDF - 1.7 MB - MD5: 1030cdbea17dd5b867e3cbd1f31aae73
Case Report Form
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.